CD160 and neoplasm: MDA-MB-231 and IJG1731 were selected to assess tumor depletion on low and high CD160-TM expressing cells, respectively (see expression level in Fig. 2c, corresponding to A12/control Ab MFI ratio = 2.2 and 8.9 for MDA-MB-231 and IJG1731, respectively).